Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArulananda, Surein-
dc.contributor.authorLee, Erinna F-
dc.contributor.authorFairlie, W Douglas-
dc.contributor.authorJohn, Thomas-
dc.identifier.citationExpert Review of Anticancer Therapy 2020; online first: 26 Novemberen
dc.description.abstractWith limited therapeutic changes in over a decade, a diagnosis of malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies worldwide. Due to unregulated asbestos use in developing countries and through exposure associated with home renovations rather than industrial exposure, as was the case in the past, new cases of MPM are likely to present for decades to come. As MPM is largely driven by dysregulation of tumour suppressor genes, researchers have looked to other mechanisms of subverting tumour proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs a cell's ability to undergo programmed cell death and BH3-mimetics which target these proteins, are a novel treatment option across haematological and some solid cancers, though have yet to be widely investigated in MPM. This review provides a succinct overview of MPM and its current treatment landscape. It summarises the role that BCL-2 family proteins play in tumorigenesis and the current therapeutic potential of BH3-mimetics across multiple cancer types. Finally, it discusses the role that BCL-2 family proteins play in MPM and the pre-clinical rationale for investigating BH3-mimetics as a therapeutic strategy. As a disease which lacks readily actionable oncogene driver mutations and displays only a modest benefit from immune checkpoint inhibition, novel therapeutic options are urgently needed for MPM. Hence, BH3-mimetics could be a promising treatment option for some solid cancers and potentially for MPM, where there is evidence supporting dependence on pro-survival BCL-2 proteins for MPM tumour cell survival.en
dc.subjectBCL-2 family proteinsen
dc.subjectcell deathen
dc.subjectmalignant pleural mesotheliomaen
dc.titleThe role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University , Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University , Heidelberg, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre , Melbourne, Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.pubmedid33238762-, Thomas
item.fulltextNo Fulltext-
item.openairetypeJournal Article- Newton-John Cancer Research Institute- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 23, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.